Effects of Pau d' Arco in Primary Dysmenorrhea

  • STATUS
    Recruiting
  • participants needed
    12
  • sponsor
    National University of Natural Medicine
Updated on 19 February 2024
fasting
dysmenorrhea
copper
paragard

Summary

A single arm, open-label trial evaluating safety and tolerability of encapsulated Tabebuia avellanedae in 12 generally healthy women aged 18-45 with primary dysmenorrhea (PDM). This will be the first study evaluating the safety and tolerability of Tabebuia avellanedae in PDM. We also aim to collect proof-of-concept mechanistic data supporting the hypothesis that Tabebuia avellanedae reduces PGE2 concentration in vivo in women with PDM.

Description

This is a single arm, open-label trial evaluating safety and tolerability of 1,050 mg/day of encapsulated Tabebuia avellanedae every day for 2 months, as well as effects of the treatment on quality of life, pain intensity, and pain interference, in 12 generally healthy women aged 18-45 with PDM. Outcomes of this study include questionnaires to evaluate: safety and tolerability using standardized adverse events scales (primary); participant reported measurements of quality of life, pain intensity, and pain interference around menses collected on validated instruments (secondary); and blood concentration of PGE2 and high-sensitivity C-reactive protein (tertiary). The protocol followed the SPIRIT guidelines and fulfilled the SPIRIT checklist.

Details
Condition Primary Dysmenorrhea
Age 18-45 years
Treatment Pau d' Arco
Clinical Study IdentifierNCT04245540
SponsorNational University of Natural Medicine
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Biologically female
Ages 18-45
Presence of primary dysmenorrhea
Has a 'smart' phone and is willing to download and use an electronic application for use during the study
Willing to take a non-hormonal form of birth control throughout the trial period (abstinence, condom, diaphragm, or copper IUD (ParaGard))
Lives in the Portland area
Able to speak, read and write English
Has reliable transportation to clinic
Willing to have four fasting blood draws taken
Wiling to collect menstrual fluid in a Diva cup on the first day of menstruation and ability to deliver it to the clinic on the same day
Ability to receive and complete electronic VAS scales
Pain scale rating of 6 or higher on the VAS scale
Monthly pain that correlates with menstruation

Exclusion Criteria

Presence of secondary dysmenorrhea
General health measures outside of normal range
Blood pressure readings obtained at the Screening Visit reveal hypotension (90/60 mmHg) or hypertension (140/90 mmHg)
Aspartate aminotransferase (AST) < 8 U/L or > 48 U/L at the Screening Visit
Alanine aminotransferase (AST) < 7 U/L or > 55 U/L at the Screening Visit
Estimated glomerular filtration rate (eGFR) < 90 ml/min/1.73m2 at the Screening Visit
An INR value > 1.1 at the Screening Visit
A red blood cell count < 3.90 million cells/mcL or > 5.03 million cells/mcL
A hemoglobin value of < 12 g/dL (120 g/L) or > 15.5 g/dL (155 g/L)
A hematocrit value of < 34.9% or > 44.5%
A white blood cell count < 3.5 billion cells/L (3,500 cells/mcL) or > 10.5 billion cells/L (10,500 cells/mcL)
A platelet count < 150 billion/L (150,000/mcL) or > 450 billion/L (450,000 mcL)
Women who are nursing, pregnant, or planning pregnancy in the next four months
Difficulty swallowing or aversion to capsules, tablets, or pills
Currently taking, and unwilling to discontinue, NSAIDs (Aspirin, Ibuprofen)
Currently taking dietary supplements with any of the following ingredients in amounts over 250 mg/day: cinnamon, garlic, ginger, turmeric, and/or curcumin
Consumption of >1 alcoholic drink per day, during the study period
Currently taking any anticoagulation medications (Warfarin/Coumadin)
Currently taking, or have taken in the past two months, hormonal forms of birth control
Unwillingness, or inability, to take a monthly pregnancy test during the timeline of the study (3 pregnancy tests)
Past or present medical history of any of the following
Blood clotting disorders (von Willebrand disease, Hemophilia A, Hemophilia B, etc.)
Liver disease (cirrhosis, hepatitis, liver failure, jaundice, liver cancer, etc.)
Kidney disease (chronic kidney disease, polycystic kidney disease, etc.)
Cardiac disease (hypertension, heart failure, cardiomyopathy, etc.)
Anemia (iron deficiency, sickle cell, aplastic, etc.)
Inflammatory bowel disease
Irritable bowel syndrome
Endometriosis
Obstructive endometrial polyps
Chronic pelvic inflammatory disease
Polycystic Ovarian Syndrome
Adenomyosis
Intrauterine or pelvic adhesions
Congenital obstructive mullerian malformations
Cervical stenosis
Use of an intrauterine contraceptive device that causes pain
Pelvic congestion syndrome
Reproductive cancer (uterine cancer, ovarian cancer, endometrial cancer, etc.)
Ovarian cysts
Fibroids
Uteropelvic junction obstruction
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.